# Gallium-68 gozetotide (PSMA-11)

Source: https://onco.cc/drugs/ga68-psma-11/  
OnCo record `ga68-psma-11` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Gallium-68 PSMA-11 was the first PSMA PET tracer approved in the US (2020), and is made on site from a generator or cyclotron.

## Summary

Gallium-68 gozetotide (PSMA-11) is a 68Ga-labelled urea-based ligand that binds prostate-specific membrane antigen, lighting up prostate cancer on PET wherever it has spread. It is made on site from a germanium-68 generator or cyclotron and used for initial staging of higher-risk disease, for biochemical recurrence, and to confirm PSMA expression before 177Lu-PSMA-617 therapy. The UCLA/UCSF academic NDA (2020) established PSMA PET in the US, followed by Telix's Illuccix kit (2021) and Gozellix (2025, longer shelf-life) and Novartis' Locametz (2022, companion for Pluvicto). It competes with 18F agents (Pylarify, Posluma) that offer central distribution and a longer half-life. Whether findings on PSMA PET should change treatment in the absence of outcome trials remains debated. In plain terms, it was the first PSMA PET tracer approved in the US.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-06
- Brand: Illuccix / Gozellix / Locametz
- Modality: PET imaging agent
- Mechanism: 68Ga-labelled urea-based PSMA ligand.
- Approvals: US 2020: PSMA PET (UCLA/UCSF NDA); kits 2021-2022

## Sources

- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Gallium-68%20gozetotide

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [PSMA PET](https://onco.cc/technologies/psma-pet/)
- targets: [PSMA](https://onco.cc/targets/psma/)
- companies: [Novartis](https://onco.cc/companies/novartis/), [Telix Pharmaceuticals](https://onco.cc/companies/telix/)
- institutions: [UCLA Jonsson Comprehensive Cancer Center](https://onco.cc/institutions/ucla-jonsson/), [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)
- trials: [PSMA PET Combined With MRI for the Detection of PCa](https://onco.cc/trials/nct07052214/), [PSMA-PreRP](https://onco.cc/trials/psma-prerp/)
- drugs: [Illuccix (kit for Ga-68 gozetotide)](https://onco.cc/drugs/illuccix/), [Locametz (kit for Ga-68 gozetotide)](https://onco.cc/drugs/locametz/)
- biomarkers: [PSMA expression by PET (PSMA-positive)](https://onco.cc/biomarkers/psma-pet-expression/)
- key papers: [Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial](https://onco.cc/key-papers/paper-psma-prerp-hope-jama-oncol-2021/)

---
JSON: https://onco.cc/api/v1/entities/ga68-psma-11.json